1. Sweden Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
IRLAB Therapeutics AB Class A

IRLAB Therapeutics AB Class A

0.10
USD
- -
- -
Nov 13Next Earn
IRLAB Therapeutics AB Class A
OTC:IRLAF
(OTC Markets)

Recent

price

0.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
SEK
- -
- -
- -
0.01
- -
- -
- -
- -
3.71
1.09
0.1
1.79
0.84
- -
Revenue per Share
- -
0.12
-0.45
-1.53
-1.51
-1.76
-2.19
-1.78
0.92
-2.02
-3.17
-1.57
-1.61
- -
Basic EPS, GAAP
- -
-0.42
-1.05
-1.47
-1.56
-1.71
-2.08
-1.74
2.28
-2.6
-2.94
-1.24
-0.81
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.89
1.81
3.3
3.72
4.02
4.76
3.83
6.63
7.13
5.18
2.06
0.58
0.35
1.14
Book Value per Share
0.89
-1.21
0.28
0.7
1.83
2.9
2.1
5.06
6.37
4.35
1.23
-0.25
-0.19
0.59
Tangible Book Value per Share
28
26
26
28
37
42
44
52
56
56
56
53
68
83
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
208
61
6
95
57
- -
Sales/Revenue/Turnover
- -
-26,807.41
- -
-31,981.25
-50,716.51
-410,538.89
-368,930.77
- -
25.24
-185.2
-3,183.62
-78.84
-151.44
- -
Operating Margin (%)
- -
- -
- -
- -
- -
1
3
2
3
4
4
5
8
- -
Depreciation Expense
- -
3
-12
-43
-56
-74
-96
-92
52
-113
-178
-83
-110
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
5,781.48
- -
-29,650
-51,582.57
-411,661.11
-369,692.31
- -
24.92
-185.5
-3,132.07
-87.85
-191.45
- -
Profit Margin (%)
- -
16
11
19
70
128
97
263
352
236
87
-20
-22
47
Working Capital
- -
- -
- -
- -
- -
- -
3
1
4
- -
25
4
- -
- -
LT Debt
25
89
92
104
155
212
182
348
399
291
116
33
31
97
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
13.89
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
13.78
- -
- -
- -
- -
- -
Return on Capital (%)
- -
8.26
-16.67
-43.59
-43.44
-40.33
-48.75
-34.61
13.86
-32.86
-87.48
-112.03
-347.29
- -
Return on Common Equity (%)

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
30
27
24
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
87
87
85
Market Capitalization
- -
- -
- -

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
88
84
132
Cash, Cash Equivalents & STI
82
51
34
Accounts Receivable, Net
4
33
98
Inventories
- -
- -
- -
Total Current Liabilities
110
95
85
Payables & Accruals
- -
- -
- -
ST Debt
30
27
24
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.58%
-30.05%
-5.87%
Free Cash Flow
-38.12%
-104%
-16.06%
Net Income, GAAP
-9.19%
-87.92%
32.34%
Sales/Revenue/Turnover
- -
- -
-39.28%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
43
9
43
95
2025
4
20
- -
15
57
2026
39
6
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.69
-0.13
-0.6
-0.1
-1.57
2025
-0.64
-0.62
- -
-0.28
-1.61
2026
0.11
-0.23
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
IRLAB Therapeutics AB (publ) IRLAB Therapeutics AB (publ) (Nasdaq Stockholm: IRLAB A) operates as a Sweden-based research and development company focused on discovering and developing novel small-molecule drugs for Parkinson's disease and other central nervous system (CNS) disorders; it employs its proprietary Integrative Screening Process (ISP) platform, a systems pharmacology approach leveraging a proprietary database of CNS compounds accumulated over 25 years, to generate drug candidates targeting various disease stages including levodopa-induced dyskinesias (LIDs), psychosis, falls, dementia, apathy, and cognitive impairment. The company's primary pipeline includes mesdopetam (IRL790) in Phase III preparation for PD-LIDs, pirepemat (IRL752) in Phase IIb for PD-psychosis and falls risk reduction, IRL757 in Phase I for neurology-apathy (in collaboration with The Michael J. Fox Foundation and MSRD/Otsuka Pharmaceutical), and preclinical candidates IRL942 for PD-dementia/cognitive impairment and IRL1117 for core Parkinson's motor symptoms without levodopa complications; all candidates originate from ISP and aim to address unmet needs in neurodegenerative diseases affecting nearly 11 million patients globally, with projections to double by 2040. Founded in 2013 from Nobel Laureate Prof. Arvid Carlsson's research group and headquartered at Arvid Wallgrens Backe 20 in Gothenburg, Sweden, IRLAB conducts operations primarily in Europe with global partnership ambitions and lists on Nasdaq Stockholm's Main Market since 2020. Recent developments encompass a June 2025 rights issue raising approximately SEK 136 million before costs to fund clinical/preclinical advancement, business development, and capital strengthening with strong backing from major shareholders including FV Group AB, Fjärde AP-fonden, and senior management; extension of a SEK 55 million Fenja Capital loan; full funding secured for IRL757 Phase Ib study via MSRD/Otsuka collaboration with patient recruitment planned for Q4 2025; positive Phase I results for IRL757 in May 2025; strengthened patent protections including a May 2025 grant; and progress toward Phase III for mesdopetam with favorable regulatory feedback from US and European authorities.